Abbott To Launch Libre Duo Glucose Sensor In December
The new dual-sensing device will enter the United States market following its recent FDA clearance.
Updated on Oct. 21, 2026 in Diabetes
Live Poll
Do you feel new medical devices are making diabetes management more affordable for your household?
Abbott plans to launch its Libre Duo glucose and ketone sensor in the United States in December 2026. The company secured FDA de novo clearance for the device in August 2026.
Why it matters
The Libre Duo sensor provides both glucose and ketone tracking to help users identify potential risks for diabetic ketoacidosis. Abbott expects the product to serve as a significant growth driver for the company in 2027.
The system monitors ketone levels alongside glucose to proactively flag diabetic ketoacidosis risks. Payer formulary coverage for the new device is officially scheduled to go into effect on January 1, 2027.
The players
Abbott
Abbott is a global medical device and health care company that produces diagnostic tools and glucose monitoring systems.
The details
The Libre Duo device expands upon traditional glucose monitoring by including ketone detection. Following an international release in the fall of 2026, the device will debut domestically to support patients managing their blood sugar levels.
Timeline
May 2026: Abbott received the CE Mark for the sensor.
August 2026: The company received FDA de novo clearance.
Fall 2026: The device launched internationally.
December 2026: The Libre Duo is scheduled to launch in the United States.
January 1, 2027: New payer formulary coverage goes into effect.
Health Landscape
The introduction of the Libre Duo extends the existing standard of care for diabetic ketoacidosis monitoring by enabling continuous ketone tracking. This launch marks a shift in clinical management by integrating ketone detection into a continuous glucose-monitoring platform.
Users will gain access to dual-sensor technology designed to detect ketone levels, which can help manage the risk of diabetic ketoacidosis. Patients should monitor their insurance providers for coverage updates beginning on January 1, 2027.
The takeaway
The addition of ketone tracking to glucose-monitoring devices offers a new tool for preventing serious diabetes-related complications. Patients should consult their healthcare providers to discuss how this technology fits into their ongoing treatment plan.
What happens next
Payer formulary coverage for the Libre Duo system is scheduled to go into effect on January 1, 2027.
Further reading
For more information on the management of blood sugar, visit the United States Diabetes section.
Source note: This article includes information reported by MassDevice.
Live Poll
Do you feel new medical devices are making diabetes management more affordable for your household?
